BOSTON, Massachusetts — May 5, 2026 — Leads & Copy —
Compass Therapeutics, Inc. (Nasdaq: CMPX) reported its first quarter 2026 financial results and provided a business update. The company, which is focused on oncology, is developing antibody-based therapeutics to treat multiple human diseases.
The company’s tovecimig (DLL4 x VEGF-A bispecific antibody), in combination with paclitaxel, demonstrated a statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone in a Phase 2/3 study of patients with biliary tract cancer (BTC). The study also showed clear signals of a survival benefit. Tovecimig previously met the primary endpoint of overall response rate (ORR). The company intends to meet with the FDA in advance of its planned BLA submission later this year.
Compass Therapeutics’ Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The study highlighted three deep responses (TNBC, NSCLC, HL) in patients treated in the post-checkpoint inhibitor setting. The company has initiated cohort expansions in these indications.
The Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) has also been initiated in the post-checkpoint inhibitor setting, with initial data expected in the fourth quarter of 2026.
Compass Therapeutics reported $195 million in cash and marketable securities at the end of the first quarter of 2026. The company expects this to fund operations into 2028.
According to Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors, tovecimig would be a compelling treatment alternative for patients with BTC who have no approved therapeutic option in the second line setting.
The company also provided the following pipeline updates:
Tovecimig (DLL4 and VEGF-A bispecific antibody)
The company announced data from its Phase 2/3 study of tovecimig, which it plans to include in a BLA submission, to treat patients with biliary tract cancer in the second line setting:
Overall Response Rate (primary endpoint): 17.1% for tovecimig combination (n=111), including one complete response, compared to 5.3% for paclitaxel alone (n=57)(p=0.031).
Progression-Free Survival (secondary endpoint): 4.7 months for tovecimig combination compared to 2.6 months for paclitaxel alone (HR=0.44, p<0.0001).
Overall Survival (secondary endpoint): The OS of the patients randomized to the tovecimig combination arm (n=111) was a median of 8.9 months.
PFS Before / After Crossover (secondary endpoint): Patients treated with tovecimig after crossing from the control arm progressed after a median 3.5 months (PFS2) in the third line setting. These same 31 patients, when initially randomized to paclitaxel alone (PFS1), had progressed more quickly, with a median of 1.9 months in the second line setting (HR=0.36, p=0.0016).
OS Crossover vs. Non-Crossover (post hoc subset analysis): Crossover patients who subsequently received tovecimig demonstrated a statistically significant improvement in median OS of 12.8 months compared to 6.1 months for non-crossover patients who received only paclitaxel (n=26)(HR=0.54, p=0.04).
Pooled OS of All Patients Treated with Tovecimig (post hoc subset analysis): For all patients treated with tovecimig, including both crossover patients and patients initially randomized to the tovecimig combination arm (n=142), the pooled median OS was 9.8 months. The median OS for patients randomized to the paclitaxel alone who did not crossover (n=26) was 6.1 months.
Safety: Tovecimig was generally well tolerated and the safety profile was consistent with prior studies, with no new safety signals identified.
The investigator sponsored trial (IST) of tovecimig in combination with the current first-line, standard-of-care regimen of gemcitabine, cisplatin, and durvalumab in patients with BTC (NCT05506943) is ongoing. The company is evaluating multiple additional studies for tovecimig in other indications, including both ISTs and Company-sponsored studies.
CTX-8371 (PD-1 x PD-L1 bispecific antibody)
Cohort expansions for CTX-8371 have been initiated in patients with triple-negative breast cancer (TNBC, n=28), non-small cell lung cancer (NSCLC, n=28), and Hodgkin lymphoma (HL, n=12) in the post-checkpoint inhibitor setting.
Initial data from these cohort expansions, as well as available data from the Phase 1 dose-escalation portion of the study, will be presented at ASCO 2026. Additional data from the cohort expansions are expected in the fourth quarter of 2026.
CTX-10726 (PD-1 x VEGF-A bispecific antibody)
The Phase 1 study has been initiated with clinical data expected in the fourth quarter of 2026.
The Phase 1 multiple ascending dose-escalation study will include four doses (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 dose-escalation design. The multi-center study will enroll patients with a prioritized set of solid tumor indications.
CTX-471 (CD137 or 4-1BB agonist antibody)
Initiation of the Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56) is expected in the second half of 2026.
For the quarter ended March 31, 2026, Compass Therapeutics reported a net loss of $18.3 million, or $0.10 per common share, compared to a net loss of $16.6 million, or $0.12 per common share, for the same period in 2025.
R&D expenses were $13.4 million for the quarter ended March 31, 2026, as compared to $13.1 million for the same period in 2025.
G&A expenses were $6.9 million for the quarter ended March 31, 2026, as compared to $4.9 million for the same period in 2025.
As of March 31, 2026, cash and marketable securities were $195 million as compared to $209 million as of December 31, 2025.
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Source: Compass Therapeutics, Inc.
